Assessment of Some Biochemical Markers In Patients with Beta Thalassemia Major
DOI:
https://doi.org/10.46966/msjar.v6i3.308Keywords:
Beta Thalassemia, Biochemical Marker, Thalassemic patientsAbstract
AbstractBackground: The hereditary state red blood cells are harmed by beta-thalassemia's poor hemoglobin (Hb) production. A reduced capacity to synthesis one or more globin chains is its defining feature. For patients with this illness to survive, multiple blood transfusions are necessary. Objective: to examine serum level of serum lipid profiles (Total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low-density lipoprotein (VLDL. Materials and Methods: forty-five patients with β-thalassemia major and forty-five healthy control groups were involved in the present study. Serum lipid profile level in addition to BMI and CRP for both patient and control groups were measured. Results: Serum TC, HDL-C, LDL-C and BMI revealed significant decreasing in patients with β-thalassemia major as comparing with healthy subjects. The findings of TC, HDL-C, LDL-C and BMI which exhibited through this study are, (117.14 ± 14.22 vs 87.26 ± 11.85, P< 0.001), (25.09 ± 2.96 vs 32.15 ± 6.92, P< 0.001), (66.39 ± 14.83 vs 86.13 ± 19.57, P< 0.001) and (19.32 ± 3.26 vs 22.52 ± 3.61, P< 0.001) respectively. Serum level of TG, VLDL-C and CRP manifested significant higher in patients than in healthy subjects. Conclusion: In the current study, TC, HDL-C, LDL-C and BMI revealed significant decreasing in patients with β-thalassemia major as comparing with healthy subjects while Serum level of TG, VLDL-C and CRP manifested significant higher in patients than healthy subjects
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Nabaa K. Alqurashi, Mohammed K.S.
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
